Rivastigmine
A cholinesterase inhibitor used to treat mild to moderate dementia associated with Alzheimer's disease and Parkinson's disease, by preventing the breakdown of acetylcholine in the brain. It is available as capsules, oral solution, and a skin patch that many patients find easier to tolerate.
Masse moléculaire
250,3400 g/mol
LogP
2,30
TPSA
32,80 Ų
Règle des 5 de Lipinski
Conforme
Aires thérapeutiques
Mécanisme d'action
Inhibits acetylcholinesterase, the enzyme that hydrolyzes acetylcholine in the synaptic cleft. This increases acetylcholine availability at cholinergic synapses, enhancing cholinergic neurotransmission.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits acetylcholinesterase, the enzyme that hydrolyzes acetylcholine in the synaptic cleft. This increases acetylcholine availability at cholinergic synapses, enhancing cholinergic neurotransmission.
Structure 2D
Cite this structure
Embed this structure
SMILES
CCN(C)C(=O)Oc1cccc([C@H](C)N(C)C)c1
InChI
InChI=1S/C14H22N2O2/c1-6-16(5)14(17)18-13-9-7-8-12(10-13)11(2)15(3)4/h7-11H,6H2,1-5H3/t11-/m0/s1
Molecular Formula
C14H22N2O2
HBD / HBA
- / 3
Liaisons Rotatives
5
Atomes Lourds
18
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Foire aux questions
A cholinesterase inhibitor used to treat mild to moderate dementia associated with Alzheimer's disease and Parkinson's disease, by preventing the breakdown of acetylcholine in the brain. It is available as capsules, oral solution, and a skin patch that many patients find easier to tolerate.
Inhibits acetylcholinesterase, the enzyme that hydrolyzes acetylcholine in the synaptic cleft. This increases acetylcholine availability at cholinergic synapses, enhancing cholinergic neurotransmission.
Yes, Rivastigmine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL636. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 77991. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="rivastigmine"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/rivastigmine/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/rivastigmine/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/rivastigmine/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="rivastigmine"></drugfyi-drug>